JUŘICA, Jan a Alexandra ŽOURKOVÁ. Dynamics and persistence of CYP2D6 inhibition by paroxetine. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. HOBOKEN: WILEY-BLACKWELL, 2013, roč. 38, č. 4, s. 294-300. ISSN 0269-4727. Dostupné z: https://dx.doi.org/10.1111/jcpt.12042.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Dynamics and persistence of CYP2D6 inhibition by paroxetine
Autoři JUŘICA, Jan (203 Česká republika, garant, domácí) a Alexandra ŽOURKOVÁ (203 Česká republika, domácí).
Vydání JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, HOBOKEN, WILEY-BLACKWELL, 2013, 0269-4727.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30104 Pharmacology and pharmacy
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 1.533
Kód RIV RIV/00216224:14740/13:00065968
Organizační jednotka Středoevropský technologický institut
Doi http://dx.doi.org/10.1111/jcpt.12042
UT WoS 000321339800006
Klíčová slova anglicky CYP2D6; disinhibition; paroxetine
Štítky ok, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Olga Křížová, učo 56639. Změněno: 10. 12. 2013 10:21.
Anotace
What is known and Objective Paroxetine is both a substrate and an inhibitor of CYP2D6. The objective of the presented study was to determine the persistence of CYP2D6 inhibition after short term (6 weeks) and long term (18,7 +/- 10,6 weeks) paroxetine treatment. Methods: Two the studies consisted of 30 depressive/anxiety patients each. In the first study, patients were subdivided into three groups treated with paroxetine (A1), alprazolam (A2) and paroxetine + alprazolam (A3). After 6 weeks, all the patients (A1+A2+A3) were switched to alprazolam treatment; metabolic activity was evaluated at the beginning, after 6 weeks of paroxetine/alprazolam/alprazolam + paroxetine treatment (A1/A2/A3) and 4 weeks after the switch to alprazolam treatment (Week 0, 6, 10). In the second study patients on previous long term paroxetine treatment were subdivided into two groups treated with mirtazapine (B1) or paroxetine (B2); metabolic activity of CYP2D6 was evaluated at the beginning and after 6 weeks of therapy. Results and Discussion: Metabolic ratio of dextromethorphan to dextrorphan has normalized in all subjects after 4 weeks of paroxetine wash out in the first study. In the second study, 6 weeks after paroxetine discontinuation, restoration of metabolic activity of CYP2D6 was observed in only five of eight originally poor metabolizers. What is new and Conclusion: We conclude that a wash-out period of 4 weeks seems to be sufficient for CYP2D6 disinhibition after short-term paroxetine treatment (6 weeks). On the other hand, treatment with a CYP2D6 substrate less than 6 weeks after long-term paroxetine treatment (18.7 weeks on average) could result in elevated drug plasma levels and occasionally also in drug toxicity.
Návaznosti
ED1.1.00/02.0068, projekt VaVNázev: CEITEC - central european institute of technology
GAP206/10/0057, projekt VaVNázev: Miniaturizovaný systém pro "on-line" studie metabolismu léčiv založený na kapilární elektroforéze
Investor: Grantová agentura ČR, Miniaturizovaný systém pro "on-line" studie metabolismu léčiv založený na kapilární elektroforéze
VytisknoutZobrazeno: 3. 5. 2024 22:33